Diuril

Nephrotic Syndrome, Ascites, Edema + 23 more

Treatment

30 FDA approvals

20 Active Studies for Diuril

What is Diuril

Hydrochlorothiazide

The Generic name of this drug

Treatment Summary

Hydrochlorothiazide is a diuretic used to treat fluid retention and high blood pressure. It is the most commonly prescribed thiazide diuretic, but its use is declining in favor of other medications like angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Hydrochlorothiazide was approved by the FDA in 1959 and is available in combination with other medications.

Esidrix

is the brand name

Diuril Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Esidrix

Hydrochlorothiazide

1959

2181

Approved as Treatment by the FDA

Hydrochlorothiazide, also called Esidrix, is approved by the FDA for 30 uses including calcium channel blockers and Left Ventricular Hypertrophy .

calcium channel blockers

Used to treat calcium channel blockers in combination with Eprosartan

Left Ventricular Hypertrophy

Used to treat Left Ventricular Hypertrophy in combination with Losartan

prophylaxis of preeclampsia

Helps manage prophylaxis of preeclampsia

Premenstrual tension with edema

Helps manage Premenstrual tension with edema

Congestive Heart Failure

Used to treat Congestive Heart Failure (CHF) in combination with Spironolactone

Hypertension

Used to treat blood pressure inadequately controlled with monotherapy in combination with Irbesartan

Hypertension, Essential Hypertension

Used to treat Hypertension, Essential Hypertension in combination with Spironolactone

Antepartum magnesium sulfate prophylaxis

Helps manage prophylaxis of preeclampsia

inadequate response to other therapeutic measures

Used to treat inadequate response to other therapeutic measures in combination with Spironolactone

Hypertension

Used to treat Antihypertensive Treatment in combination with Eprosartan

Swollen feet or ankles

Used to treat Edema in combination with Triamterene

Diuretics

Used to treat Hypokalemia caused by diuretics in combination with Amiloride

Hypertensive disease

Used to treat Hypertension, Essential Hypertension in combination with Spironolactone

Hypertrophy, Left Ventricular

Used to treat Left Ventricular Hypertrophy in combination with Losartan

Stroke

Used to treat Cerebrovascular Accident in combination with Losartan

Edema

Used to treat Edema in combination with Triamterene

Cirrhosis of the Liver

Used to treat Cirrhosis of the Liver in combination with Spironolactone

Nephrotic Syndrome

Used to treat Nephrotic Syndrome in combination with Spironolactone

Hypertension

Used to treat inadequate control of blood pressure with monotherapy in combination with Aliskiren

Congestive Heart Failure (CHF)

Used to treat Congestive Heart Failure (CHF) in combination with Spironolactone

Hypokalemia

Used to treat hypokalemia with solo treatment in combination with Triamterene

Ascites

Used to treat Ascites in combination with Spironolactone

Therapeutic procedure

Used to treat inadequate response to treatment in combination with Spironolactone

Ascites

Used to treat Ascites in combination with Spironolactone

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Losartan

Sodium retention

Used to treat Sodium retention in combination with Spironolactone

Bedrest

Used to treat Bedrest in combination with Spironolactone

Cirrhosis

Used to treat Cirrhosis of the Liver in combination with Spironolactone

restriction of fluid and sodium

Used to treat restriction of fluid and sodium in combination with Spironolactone

Edema

Helps manage Premenstrual tension with edema

Effectiveness

How Diuril Affects Patients

Hydrochlorothiazide helps the body get rid of extra water and salt by preventing them from being reabsorbed in the kidneys. The amount of the drug taken can range from 25-100mg, depending on the individual. People with reduced kidney or liver function should be careful when taking this drug.

How Diuril works in the body

Hydrochlorothiazide works by blocking sodium from being reabsorbed by cells in the distal convoluted tubule, a part of the kidney. It is transported to these cells by special transporters, and then moved to the lumen of the tubule. Normally, sodium is reabsorbed into these cells and pumped into the surrounding area. This creates a concentration gradient that attracts water. By blocking sodium reabsorption, hydrochlorothiazide reduces the size of this gradient and therefore the reabsorption of water.

When to interrupt dosage

The suggested measure of Diuril is governed by the diagnosed circumstance, such as Antepartum magnesium sulfate prophylaxis, blood pressure inadequately managed with monotherapy and antihypertensives. The magnitude of dosage is contingent upon the technique of delivery (e.g. Tablet, coated - Oral or Oral) as found in the table beneath.

Condition

Dosage

Administration

Hypertrophy, Left Ventricular

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Nephrolithiasis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Therapeutic procedure

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hypertensive disease

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hypertension

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Edema

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Sodium retention

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Antepartum magnesium sulfate prophylaxis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Diabetes Insipidus

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Congestive Heart Failure

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Cirrhosis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hypertension

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hypokalemia

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Hypertension

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Swollen feet or ankles

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Renal tubular acidosis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

restriction of fluid and sodium

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

calcium channel blockers

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Diuretics

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

prophylaxis of calcium nephrolithiasis

12.5 mg, , 25.0 mg, 50.0 mg, 15.0 mg, 6.25 mg, 0.25 mg, 0.125 mg, 100.0 mg, 2.5 mg/mg, 5.0 mg/mg, 30.0 mg, 0.0125 mg

Oral, Tablet, film coated, Tablet, film coated - Oral, , Tablet, Tablet - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Diuril Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Anuria

Do Not Combine

There are 20 known major drug interactions with Diuril.

Common Diuril Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Hydrochlorothiazide may increase the hypotensive activities of Amifostine.

Cyclopentamine

Major

The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cyclopentamine.

Dofetilide

Major

The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Dofetilide.

Fenofibrate

Major

The therapeutic efficacy of Fenofibrate can be decreased when used in combination with Hydrochlorothiazide.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Hydroxyzine.

Diuril Toxicity & Overdose Risk

The lowest toxic dose of hydrochlorothiazide in mice and rats is greater than 10g/kg. If someone has overdosed on this drug, they may experience low levels of potassium, chloride, and sodium in their blood, and should be treated with fluids, electrolytes, and oxygen to restore their health. In cases of low blood pressure, vasopressors may also be administered.

Diuril Novel Uses: Which Conditions Have a Clinical Trial Featuring Diuril?

158 active clinical trials are currently assessing the potential of Diuril for managing Cirrhosis, Edema and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Cirrhosis

54 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 4, Phase 1, Early Phase 1

prophylaxis of calcium nephrolithiasis

0 Actively Recruiting

Antepartum magnesium sulfate prophylaxis

24 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1, Phase 3

Ascites

2 Actively Recruiting

Phase 2, Not Applicable

Sodium retention

0 Actively Recruiting

Swollen feet or ankles

3 Actively Recruiting

Phase 2, Not Applicable

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

inadequate response to other therapeutic measures

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Diuretics

0 Actively Recruiting

restriction of fluid and sodium

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Hypertrophy, Left Ventricular

4 Actively Recruiting

Not Applicable, Phase 4, Phase 2

Nephrotic Syndrome

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

calcium channel blockers

0 Actively Recruiting

Hypokalemia

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Bedrest

1 Actively Recruiting

Not Applicable

Diuril Reviews: What are patients saying about Diuril?

1

Patient Review

7/3/2011

Diuril for Prevention of Calcium-Containing Kidney Stones

Do not recommend. I experienced an increase in headaches and nausea after taking this for only a month, then suddenly developed severe leg and foot cramps that landed me in the ER with low sodium levels.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about diuril

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of diuretic is Diuril?

"Diuril is a prescription medication used to treat the symptoms of edema and hypertension. It may be used alone or in combination with other medications. Diuril works by increasing the amount of urine produced, which helps rid the body of excess water and salt."

Answered by AI

What is Diuril used for?

"This medication is used to lower high blood pressure in order to prevent strokes, heart attacks, and kidney problems. Chlorothiazide is a diuretic that helps remove excess salt and water from the body by increasing urine output."

Answered by AI

How long does it take Diuril to work?

"After taking chlorothiazide, you will start urinating more frequently within two hours."

Answered by AI

Is Diuril a hydrochlorothiazide?

"The drugs chlorothiazide and hydrochlorothiazide are diuretics that are used to treat nephrogenic diabetes insipidus, high blood pressure, abdominal fluid retention, heart failure, and elevated levels of calcium in the blood."

Answered by AI

Clinical Trials for Diuril

Image of Caridad Center, Inc. in Boynton Beach, United States.

CHW Nutrition Support for Type 2 Diabetes

18+
All Sexes
Boynton Beach, FL

This study tests whether adding CHW support to usual nutrition care helps adults with type 2 diabetes, hypertension, or chronic kidney disease manage their diet and health. At Caridad Center, a free clinic in Palm Beach County, Florida, usual care includes medical nutrition therapy from a registered dietitian and medically tailored groceries. Many patients find it hard to keep up dietary changes because of limited nutrition knowledge, cooking skills, food costs, and cultural fit. Two hundred adults will be randomly assigned to usual care or usual care plus INTEGRATE-CHW, a 12-week program of six sessions with a trained CHW. In each session the participant selects one or two goals from the dietitian's plan and builds an action plan with the CHW. The dietitian remains responsible for the nutrition plan. The study will compare nutrition self-efficacy, nutrition literacy, diet quality, food security, and clinical measures between groups at baseline and Week 12. It will also evaluate how well the program fits into routine clinic care.

Waitlist Available
Has No Placebo

Caridad Center, Inc.

Janet Diaz Martinez

Image of Satellite Healthcare - Daly City in San Francisco, United States.

Blood Pressure Management for Kidney Failure

18+
All Sexes
San Francisco, CA

The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study. Researchers will compare two goals for the top blood pressure number (systolic blood pressure): below 120 mmHg versus below 140 mmHg.This pilot study will help plan a larger trial in the future. Participants will: * Be assigned by chance to one of the two blood pressure goals. * Have their blood pressure measured at clinic visits about every two weeks. * Work with their kidney doctor on recommended changes to fluid management, peritoneal dialysis treatment, or blood pressure medicines to reach their assigned goal. * Be part of the study for about four and a half months.

Recruiting
Has No Placebo

Satellite Healthcare - Daly City (+2 Sites)

Chi-yuan Hsu, MD, MS

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Orlando Health Orlando Regional Medical Center in Orlando, United States.

EUS-Guided Coil and Glue for Gastric Varices

18+
All Sexes
Orlando, FL

Gastric variceal bleeding is a life-threatening complication of portal hypertension in patients with cirrhosis and is associated with significant morbidity and mortality. Endoscopic cyanoacrylate glue injection is the current standard treatment; however, recurrent bleeding and procedure-related complications remain important concerns. Endoscopic ultrasound (EUS)-guided coil and cyanoacrylate glue injection has emerged as a promising alternative that may improve variceal obliteration and reduce rebleeding rates. This prospective, randomized, open-label, parallel-group trial will compare EUS-guided coil and cyanoacrylate glue injection with conventional endoscopic cyanoacrylate glue injection in patients with cirrhosis presenting with bleeding gastric varices. A total of 158 participants will be randomized in a 1:1 ratio to either treatment arm. The primary outcome is all-cause rebleeding at 12 months. Secondary outcomes include technical success, early and late rebleeding, number of treatment sessions required for variceal obliteration, glue volume used, procedure-related adverse events, hepatic decompensation, duration of hospital stay, cost of treatment, and mortality.

Recruiting
Has No Placebo

Orlando Health Orlando Regional Medical Center

Have you considered Diuril clinical trials?

We made a collection of clinical trials featuring Diuril, we think they might fit your search criteria.
Go to Trials
Image of Kaiser Permanente Division of Research in Pleasanton, United States.

Digital Outreach for Congestive Heart Failure

18+
All Sexes
Pleasanton, CA

The goal of the ADHERE-HF study is to evaluate whether care-embedded, operationally delivered digital outreach improves medication refill, adherence, and clinical outcomes among adults with heart failure who are overdue for a refill of an eligible guideline-directed medical therapy (GDMT) medication. The main question it aims to answer is: Does digital outreach using interactive text messages or automated telephone calls increase short-term refill of overdue heart failure medications compared with usual care? The study will evaluate the effectiveness of a digital outreach strategy delivered through existing health system communication channels. Members who have opted in to pharmacy text messaging will receive interactive text messages, while those who have not opted in will receive an interactive automated telephone call. The comparison group will receive usual care with no additional outreach.

Waitlist Available
Has No Placebo

Kaiser Permanente Division of Research

Image of Hillcrest Medical Center in Tulsa, United States.

Pedal Pump for Swelling in the Legs

18+
All Sexes
Tulsa, OK

Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal exercise. However, due to the limitation of human practitioners, research has been limited. The Pedal Pump is now a device which facilitates consistency in treatment and allows for increased sample size in research. This clinical trial studies the effects of 10 minutes of Pedal Pump treatment for hospitalized patients with lower extremity edema, almost the same as Pedal Pump Clinical Trial on Edema V1 that is underway; however, this study focuses primarily on the objective data gathered by trained Occupational Therapists who regularly measure lower extremities. Key Question for this second study: Is the Pedal Pump a feasible treatment for hospitalized patients? Secondary question: Does the Pedal Pump decrease lower extremity edema? This is a novel idea in its early stage of development, so Investigators anticipate product advancements, further testing with larger population sizes, and future publications.

Recruiting
Device

Hillcrest Medical Center

Hillcrest

Image of University of California San Francisco in San Francisco, United States.

Self-Management Programs for Pain in Liver Cirrhosis

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to test a low-touch vs high-touch drug-free pain self-management program that may help lower pain and improve quality of life for adults with cirrhosis and pain. Participants are assigned by chance to one of two study groups. The groups receive different levels of support. The main questions it aims to answer are: * Do the programs help lower pain? * Do the programs improve quality of life? * Is one program more effective than the other? Researchers will compare a low-touch self management program to a high-touch self-management program to see if the programs help manage pain. Participants in the low-touch arm will: * Learn new ways to manage pain without medication * Receive access to the self-guided digital self-management platform * Receive general behavioral text message nudges * Receive a free Fitbit to keep Participants in the high-touch arm will: * Learn new ways to manage pain without medication * Receive tailored access to the self-guided digital self-management platform * Received individualized pain coaching and optional group coaching sessions * Participate in a structured walking or meditation curriculum * Receive a free Fitbit to keep

Waitlist Available
Has No Placebo

University of California San Francisco (+7 Sites)

Have you considered Diuril clinical trials?

We made a collection of clinical trials featuring Diuril, we think they might fit your search criteria.
Go to Trials
Image of University of Alabama at Birmingham (UAB Women and Infants Center) in Birmingham, United States.

Community Health Worker Support for Postpartum Hypertension

16 - 56
Female
Birmingham, AL

High blood pressure during or after pregnancy (such as preeclampsia, gestational hypertension, eclampsia, or Hemolysis, Elevated Liver enzymes, and Low Platelet (HELLP) syndrome) raises a mother's risk of heart disease later in life. Many patients do not return for follow-up care after delivery, missing a key window to protect their heart health. The Alabama Womb to Heart Solution (AW2H) trial will test whether pairing postpartum patients with a trained community health worker (CHW) for 6 months lowers blood pressure compared with usual care. A total of 174 postpartum patients who had pregnancy-associated hypertension or stage 2 high blood pressure will be randomly assigned (1:1) to usual care or usual care plus the AW2H CHW program. All participants receive education on measuring their own blood pressure and a pregnancy-validated home blood pressure monitor. Participants in the CHW group are also contacted regularly by a CHW for 6 months. CHWs coach home blood pressure monitoring, support taking blood pressure medications as prescribed, encourage heart-healthy habits based on the American Heart Association's Life's Essential 8 (LE8), help schedule a primary care visit, provide mother-baby education (such as safe sleep and immunizations), and offer emotional support. The main outcome is systolic blood pressure 6 months after enrollment, measured at home with the study-provided monitor while a research coordinator observes in person or by video/phone. The study will also look at diastolic blood pressure and whether participants scheduled a primary care visit. Interviews and focus groups will explore participant, CHW, and provider experiences with the program.

Recruiting
Has No Placebo

University of Alabama at Birmingham (UAB Women and Infants Center)

Jesse Rattan, PhD, MPH, RN

Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Image of Massachusetts General Hospital in Boston, United States.

Proximal Splenic Artery Embolization for Ascites

18+
All Sexes
Boston, MA

The purpose of this study is to learn whether a procedure called Proximal Splenic Artery Embolization (PSAE) can lower the need for repeat fluid drainage in adults with cirrhosis and a buildup of fluid in the abdomen (ascites) that is no longer controlled by water pills and diet. Participants in this study have already been told that a standard procedure called Trans jugular Intrahepatic Portosystemic Shunt (TIPS) is not a safe option for them. The main objectives this study aims to answer are: * Does PSAE lower how often participants need paracentesis, the procedure used to drain fluid from the abdomen? * Does PSAE lower the total amount of fluid drained each month? * Does PSAE change the pressure inside the liver's veins and the blood flow in the liver and spleen? * Does PSAE improve day-to-day symptoms, quality of life, strength, and the ability to do usual activities? * What side effects or complications happen with PSAE in this group of people? Participants will: * Undergo one PSAE procedure, during which small coils and/or plugs are placed in the artery that supplies the spleen to slow its blood flow * Have a pressure measurement taken in the liver's veins right before and right after the procedure, with a repeat measurement at 1 month * Attend follow-up visits at 1, 3, and 6 months that include blood tests, ultrasounds, symptoms and quality-of-life questionnaires, and a review of any paracentesis sessions since the last visit * Have a Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) and an ultrasound of the liver and spleen blood vessels at the start of the study and again at 6 months

Waitlist Available
Has No Placebo

Massachusetts General Hospital (+2 Sites)

Eric P. Wehrenberg-Klee, MD

Have you considered Diuril clinical trials?

We made a collection of clinical trials featuring Diuril, we think they might fit your search criteria.
Go to Trials